Highlights from the 2024 Summit on Haematological Cancers by The Binaytara Foundation

The 2024 Summit on Haematological Cancers by The Binaytara Foundation took place at the Hutton Hotel, 1808 West End Ave, Nashville, TN 37203, from October 11-13, 2024.

The 2024 Annual Summit on Hematologic Cancers provided a vital platform for healthcare professionals to deepen their understanding of hematologic malignancies.

This CME-accredited symposium gathered leading experts who delivered a comprehensive overview of current and emerging management strategies for conditions such as acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myeloproliferative neoplasms, multiple myeloma, and lymphoma.

Participants engaged in in-depth discussions that highlighted the latest scientific findings and practice-changing advances in the field.

Through case-based analyses, experts illustrated how to apply new clinical data and recommendations to optimize patient outcomes.

The program emphasized the importance of integrating various therapeutic agents into clinical practice, equipping attendees with the knowledge to enhance their approach to patient care in hematologic malignancies. Overall, the summit fostered an environment of learning and collaboration, aiming to improve the management of these complex conditions.

Doctors shared their insights on social media:

Ashwin Kishtagari:

“Superb talk by Anand Patel addressing the critical unmet need in treating accelerated and blast phase MPN at Binaytara Foundation the 2024 Summit on Hematological Cancers in Nashville. What new strategies can help tackle this high-risk phase of disease?”

Vivek Subbiah:

“Amazing dinner with hematology and transplant stalwarts.
Wow! What an incredible group of people visiting Nashville for Heme Summit 2024, great friends working around the clock to eradicate cancer.

Naveen Pemmaraju, Nitin Jain, Navneet Majhail. Big thanks to Navneet Majhail for getting us together and talking about cell therapy, CRSPR and work-life integration!”

Sanam Loghavi:

“Hemepath is extra popular at the Binaytara Foundation Hematologic Malignancies Summit.

Sameer Parikh highlighting the importance of hemepath expertise in correctly identifying Richter transformation.

DDX: CLL with prominent proliferation centers and CLL and Herpes.”

Gurbakhash Kaur:

“Sagar Lonial with an amazing talk in risk adaptive strategy in myeloma treatment!

-Escalate therapy based on risk static and cytogenetic abnormalities
-Depth of response is key, but don’t de-escalate RX if the risk of discontinuation is not clear.”

Nihar Desai:

“It’s a wrap!

On my way back from the Binaytara Foundation meeting in Nashville.

To sum it up:
1. ASCT for myeloma is NOT dead
2. Immunotherapy is the future for all things lymphoid
3. Lots to do in the myeloid space!”

Ashwin Kishtagari:

“Superb talk by Anand Patel addressing the critical unmet need in treating accelerated and blast phase MPN at Binaytara Foundation the 2024 Summit on Hematological Cancers in Nashville. What new strategies can help tackle this high-risk phase of disease?”

Jack Khouri:

“Having a great time with these two awesome docs in Nashville!”

Nitin Jain:

“With University of Chicago team at the Binaytara Foundation meeting in Nashville!

Missed Anand Patel.”

Naveen Pemmaraju:

“Meeting of the minds at the Binaytara Foundation meeting!

Amazing, inspiring session Women In Hematology led by Soni Smith.”

Fadi Haddad:

“Great overview by Naveen Pemmaraju on treatments in myelofibrosis and potential new targets and future directions at Binaytara Foundation 2024 meeting in Nashville.”

For more posts like this, visit oncodaily.com